Literature DB >> 19865087

Acute inflammatory arthritis: interleukin-1 blockade: a magic wand for gout?

Thomas Bardin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19865087     DOI： 10.1038/nrrheum.2009.213

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  9 in total

1.  British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.

Authors:  Kelsey M Jordan; J Stewart Cameron; Michael Snaith; Weiya Zhang; Michael Doherty; Jonathan Seckl; Aroon Hingorani; Richard Jaques; George Nuki
Journal:  Rheumatology (Oxford)       Date:  2007-05-23       Impact factor: 7.580

Review 2.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).

Authors:  W Zhang; M Doherty; T Bardin; E Pascual; V Barskova; P Conaghan; J Gerster; J Jacobs; B Leeb; F Lioté; G McCarthy; P Netter; G Nuki; F Perez-Ruiz; A Pignone; J Pimentão; L Punzi; E Roddy; T Uhlig; I Zimmermann-Gòrska
Journal:  Ann Rheum Dis       Date:  2006-05-17       Impact factor: 19.103

3.  Gout-associated uric acid crystals activate the NALP3 inflammasome.

Authors:  Fabio Martinon; Virginie Pétrilli; Annick Mayor; Aubry Tardivel; Jürg Tschopp
Journal:  Nature       Date:  2006-01-11       Impact factor: 49.962

4.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

5.  Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors:  Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

6.  Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.

Authors:  Hein J E M Janssens; Matthijs Janssen; Eloy H van de Lisdonk; Piet L C M van Riel; Chris van Weel
Journal:  Lancet       Date:  2008-05-31       Impact factor: 79.321

7.  A pilot study of IL-1 inhibition by anakinra in acute gout.

Authors:  Alexander So; Thibaut De Smedt; Sylvie Revaz; Jürg Tschopp
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

8.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.

Authors:  R Terkeltaub; J S Sundy; H R Schumacher; F Murphy; S Bookbinder; S Biedermann; R Wu; S Mellis; A Radin
Journal:  Ann Rheum Dis       Date:  2009-07-26       Impact factor: 19.103

9.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005.

Authors:  L Annemans; E Spaepen; M Gaskin; M Bonnemaire; V Malier; T Gilbert; G Nuki
Journal:  Ann Rheum Dis       Date:  2007-11-02       Impact factor: 19.103
  9 in total
  3 in total

Review 1.  Update on biology: uric acid and the activation of immune and inflammatory cells.

Authors:  Fabio Martinon
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

2.  Suppression of monosodium urate crystal-induced inflammation by inhibiting TGF-β-activated kinase 1-dependent signaling: role of the ubiquitin proteasome system.

Authors:  Anil K Singh; Mahamudul Haque; Kayla O'Sullivan; Mukesh Chourasia; Madhu M Ouseph; Salahuddin Ahmed
Journal:  Cell Mol Immunol       Date:  2019-09-11       Impact factor: 11.530

Review 3.  The emerging role of biotechnological drugs in the treatment of gout.

Authors:  L Cavagna; W J Taylor
Journal:  Biomed Res Int       Date:  2014-04-16       Impact factor: 3.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.